Lilly (LLY) and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/21/2026

1. INTC
2. DSX
3. GNK
4. TTEC
5. DAL
6. AWK
7. SPCX
8. III
9. DFTX
10. ABNAF

Go back to Lilly (LLY) and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate

Eli Lilly & Co. (LLY) Tops Q4 EPS by 39c, Revenues Beat; Offers FY21 EPS/Revenue Guidance

January 29, 2021 6:22 AM EST

Eli Lilly & Co. (NYSE: LLY) reported Q4 EPS of $2.75, $0.39 better than the analyst estimate of $2.36. Revenue for the quarter came in at $7.44 billion versus the consensus estimate of $7.29 billion.

"Lilly closed a complex year by delivering impressive results in the fourth quarter of... More